Oculis Holding AG (OCS) Net Income towards Common Stockholders (2022 - 2026)
Oculis Holding AG's (OCS) quarterly Net Income towards Common Stockholders came in at -$625.73 in Q1 2026, up 18.47% year-on-year from -$528.19 in Q1 2025, and down 19.08% quarter-over-quarter from -$525.49 in Q4 2025.
Oculis Holding AG (OCS) Net Income towards Common Stockholders (2022 - 2026) Analysis & Trends
Oculis Holding AG's Net Income towards Common Stockholders history runs 5 years deep, the most recent figure standing at -$625.73 for Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders rose 18.47% year-over-year to -$625.73 in Q1 2026; TTM through Mar 2026 was -$2143.1, a 19.13% increase from a year earlier, with the FY2025 full-year figure at -$2279.6, up 5.4% from the prior year.
- Net Income towards Common Stockholders retreated to -$625.73 in Q1 2026 per OCS's latest filing, from -$525.49 in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$383.3 in Q4 2023 and bottomed at -$3859.8 in Q1 2023.
- The 5-year median for Net Income towards Common Stockholders is -$577.91 (2025), against an average of -$1248.6.
- Across the five-year window, Net Income towards Common Stockholders surged 88.82% in 2023 and slumped 99.54% in 2024, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at -$2709.2 in 2022, then soared by 85.85% to -$383.3 in 2023, then slumped by 99.54% to -$764.82 in 2024, then soared by 31.29% to -$525.49 in 2025, then retreated by 19.08% to -$625.73 in 2026.
- Per Business Quant, the three latest OCS Net Income towards Common Stockholders figures stand at -$625.73 (Q1 2026), -$525.49 (Q4 2025), and -$400.04 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -0.68 |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 366.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 205.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -625.73 |
| Dec 31, 2025 | -525.49 |
| Sep 30, 2025 | -400.04 |
| Jun 30, 2025 | -591.87 |
| Mar 31, 2025 | -767.45 |
| Dec 31, 2024 | -764.82 |
| Sep 30, 2024 | -554.02 |
| Jun 30, 2024 | -563.95 |
| Mar 31, 2024 | -504.10 |
| Dec 31, 2023 | -383.30 |
| Sep 30, 2023 | -543.43 |
| Jun 30, 2023 | -422.63 |
| Mar 31, 2023 | -3,859.75 |
| Dec 31, 2022 | -2,709.24 |
| Sep 30, 2022 | -2,982.12 |
| Jun 30, 2022 | -3,779.39 |